Tuesday, September 29, 2020
News
NEWS HOME
»
PRESS RELEASES

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trialin adults with and without diabetes
  SocialTwist Tell-a-Friend  
   


Date: 30-07-2020 4:50PM
Source: Boehringer Ingelheim
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical, Manufacturing Companies
Location: Ingelheim, Germany & Indianapolis, United States

Business Wire India

- Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction

- Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1


Positive top-line results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced today by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). EMPEROR-Reduced met its primary endpoint, demonstrating superiority with empagliflozin (10 mg) compared to placebo in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure, when added to standard of care. Overall, the safety profile was similar to the known safety profile of empagliflozin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200730005445/en/

“Heart failure is a common, but very serious chronic cardiovascular disorder, and it causes substantial disability while threatening the lives of millions of people worldwide,” said Milton Packer, M.D., Chair of the Executive Committee for the EMPEROR Program and Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center in Dallas, Texas, US. “The results of the EMPEROR-Reduced trial indicate that SGLT2 inhibitors have the potential to become a new standard of care for this disease, which will be a meaningful addition to currently established treatments.”

Heart failure is the leading cause of hospitalization in the US and Europe, and the number of patients across Asia is also increasing.2 The risk of death in people with heart failure rises with each hospital admission.3 Heart failure with reduced ejection fraction occurs when the heart muscle does not contract effectively, and less blood is pumped out to the body compared to a normally functioning heart.4 Symptoms associated with heart failure, such as breathlessness and fatigue, can impact quality of life.5

“One in five people can expect to develop heart failure in their lifetime, so it is very encouraging to see these positive results from the EMPEROR-Reduced trial demonstrating that empagliflozin improves heart failure outcomes,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “We are excited to share the full results and are working tirelessly to explore how empagliflozin can improve the lives of people living with heart failure.”

Full results from the EMPEROR-Reduced trial will be presented in a hot line session at the European Society of Cardiology (ESC) congress 2020 on 29 August, and regulatory submissions are planned in 2020. A second trial, EMPEROR-Preserved, is exploring the effect of empagliflozin on cardiovascular death or hospitalization in adults with heart failure with preserved ejection fraction – an area with no approved treatment options.6,7 EMPEROR-Preserved results are expected in 2021.

The EMPEROR trials are part of the EMPOWER clinical program, one of the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic conditions.

“These results build upon the already established cardiovascular benefits of empagliflozin in adults living with type 2 diabetes and cardiovascular disease,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. “Metabolic conditions that affect the heart and kidneys can lead to serious consequences, including hospitalizations and death. Through our EMPOWER clinical program, we are committed to advancing knowledge about these devastating clinical outcomes. We look forward to seeing how empagliflozin can help adults around the world living with these conditions.”

About the EMPEROR Heart Failure Studies6,8
The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) chronic heart failure studies are two Phase III, randomized, double-blind trials investigating once-daily empagliflozin compared with placebo in adults with chronic heart failure with preserved or reduced ejection fraction*, both with and without diabetes, who are receiving current standard of care:

  • EMPEROR-Reduced [NCT03057977] investigated the safety and efficacy of empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF).
  • Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure
  • Number of patients: 3,730
  • Completion: 2020
  • EMPEROR-Preserved [NCT03057951] investigates the safety and efficacy of empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF).
  • Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure [Time Frame: up to 38 months]
  • Anticipated number of patients: approx. 5,990
  • Estimated completion: 2021

*Ejection fraction is a measurement of the percentage of blood the left ventricle pumps out with each contraction. When the heart relaxes, the ventricle refills with blood.

HFrEF occurs when the heart muscle does not contract effectively, and less blood is pumped out to the body compared with a normally functioning heart.
HFpEF occurs when the heart muscle contracts normally but the ventricle does not fill with enough blood, so less blood can enter the heart compared with a normally functioning heart.

About the EMPOWER program
The Alliance has developed the EMPOWER program to explore the impact of empagliflozin on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions. Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and account for up to 20 million deaths annually.9 Through the EMPOWER program, Boehringer Ingelheim and Lilly are working to advance knowledge of these interconnected systems and create care which offers integrated, multi-organ benefits. Comprised of nine clinical trials and a real-world evidence study, EMPOWER reinforces the long-term commitment of the Alliance to improve outcomes for people living with cardio-renal-metabolic conditions. With more than 27,000 adults enrolled worldwide in clinical trials, it is one of the broadest and most comprehensive clinical programs for an SGLT2 inhibitor to date.

About Heart Failure
Heart failure is a progressive, debilitating and potentially fatal condition that occurs when the heart cannot supply adequate circulation to meet the body’s demands for oxygenated blood or to do so requires increased blood volume leading to fluid accumulation (congestion) in the lungs and peripheral tissues.10 It is a widespread condition affecting 60 million people worldwide and expected to increase as the population ages.11 Heart failure is highly prevalent in people with diabetes;12 however, approximately half of all people with heart failure do not have diabetes.11,13

The empagliflozin heart failure program was initiated based on data from the EMPA-REG OUTCOME® trial, which assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo.14

About Cardio-Renal-Metabolic Conditions
Boehringer Ingelheim and Lilly are driven to transform care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.9

The cardiovascular, renal and metabolic systems are interconnected, and share many of the same risk factors and pathological pathways along the disease continuum. Dysfunction in one system may accelerate the onset of others, resulting in progression of interconnected diseases such as type 2 diabetes, cardiovascular disease, heart failure, and kidney disease, which in turn leads to an increased risk of cardiovascular death. Conversely, improving the health of one system can lead to positive effects throughout the others.15,16

Through our research and treatments, our goal is to support people’s health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our commitment to those whose health is jeopardized by cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling treatment gaps.

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.17,18,19

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels prevents sugar being re-absorbed by the kidneys, leading to the excretion of excess sugar in the urine. In addition, initiation of empagliflozin also prevents salt being re-absorbed, leading to increased excretion of salt from the body and reducing the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.20

Please click on the following link for ‘Notes to Editors’ and ‘References’ https://www.boehringer-ingelheim.com/press-release/emperor-reduced-heart-failure-toplineresults



CONTACTS :

Stefanie Molkenthin
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 172209

Stephan Thalen
Global Business Communications
Lilly Diabetes
Email: stephan.thalen@lilly.com
Phone: +1 (317) 276 8304

More Press Releases

Skyhook Makes Location Accessible Through Smart Feature Phone Integrations

Andersen Global Strengthens Caribbean Presence with Addition of Templar Chambers

Wenatchee Valley College Evaluates IT Environment After Local College Hit with Ransomware

Moody’s Enhances Flagship Moody’s CreditView Platform With ESG Expertise

Sintavia Acquires Two Additional M400-4 Printers from EOS GmbH

Savonix and Fujitsu Connected Technologies Limited Partner to Introduce Savonix Mobile App on Raku-Raku Smartphone F-42A

Application of Forensic DNA Technology Critical to Deter Sexual Predators as Rape Complaints Reach Pre-Pandemic Levels

Oasis Fertility’s Groundbreaking Initiative to Beat COVID Apprehensions With IVF @Home

Boehringer Ingelheim invests to further develop the pet care market in China

Three Indian’s Launch Faceless Chat the World’s First App That Turns Facebook or WhatsApp Into an Anonymous Social Network

QuantInsti Celebrates 10 Years of Serving Quant Traders Globally

Toshiba Launches Ultra-Low Current Consumption CMOS Operational Amplifier That Contributes to Longer Operating Hours of Battery-Operated Devices

Corrugated Box Industry in Distress over Rising Kraft Paper Prices and Supply Disruptions

AEA2020: October 27th to 29th Online

Rimini Street Celebrates 15 Years of Delivering Client Success

Ares Management Corporation Names John Knox as Australia & New Zealand Chairman of Ares SSG

UL Launches Bureau of Indian Standards Recognized Heating, Ventilation and Air Conditioning Testing Services for Electronic Controllers

Mavenir acquires ip.access to expand OpenRAN radio portfolio for CSPs and Enterprise Private Networks

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics

Kissflow Partners with The Digital Workplace for a First-of-Its-Kind Tweetathon on Digital Workplace Day

India Pulses and Grains Association Hosts The IPGA Knowledge Series Webinar on Kharif Crop Outlook for 2020-21 Season

MetLife to Reduce Emissions by 30 Percent and Originate $20 Billion of New Green Investments By 2030

World Tourism Day: Reviving Travel and Tourism Industry in the Post- COVID-19 World

NTT Com Demonstration Test to Link GAIA-X Platform’s “IDS Connector” Technology and SDPF Based on Data Trust®

Dramz Global LLC Announces Its Global Video Streaming App vRockk

Mintel: 41 percent of Young Indian Beer Drinkers Are Willing to Switch to Low or No Alcohol Beer

L&T Technology Services Selected to Support Tenneco DRiV™ Ride Performance Division

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Youth kills 11 pigeons to avenge 'insult...
Pakistan violates ceasefire in J-K's Man...
Four arrested in UP's Sambhal for bettin...
Maoist killed in Chhattisgarh's Bijapur...
Patnaik launches initiative to make Odis...
Teachers in Jharkhand's Dumka turn villa...
More...    
 
 Top Stories
Adam Sandler is up for reuniting wi... 
Valliappa Foundation launches 'Anad... 
'Ishq Subhan Allah' to go off air... 
Amazon sellers expect sales growth ... 
HAL rolls out 300th Dhruv chopper i... 
Amanda Seyfried gives birth to seco... 
MECL starts exploration in Kolar Go... 
Congress misleading farmers on new ...